MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03130cam a2200325 a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
EG-GiCUC |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
161011s2016 ua dh f m 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
EG-GiCUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GiCUC |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| 049 ## - LOCAL HOLDINGS (OCLC) |
|---|
| Holding library |
Deposite |
| 097 ## - Thesis Degree |
|---|
| Thesis Level |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Classification number |
Cai01.08.05.M.Sc.2016.Us.D |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Usama Mohamed Magdi Ammar |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Design, synthesis and molecular modeling of novel pyridopyrazinone derivatives of expected antineoplastic activity / |
| Statement of responsibility, etc. |
Usama Mohamed Magdi Ammar ; Supervised Kamelia M. Amin , Ossama M. El-badry , Doaa E. Abdelrahman |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
تصمييم وتشييد ونمذجة جزيئية لبعض مشتقات البيريدوبيرازينون الجديدة و المتوقع لها فاعلية مضادة للأورام السرطانية |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Cairo : |
| Name of publisher, distributor, etc. |
Usama Mohamed Magdi Ammar , |
| Date of publication, distribution, etc. |
2016 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
150 P. : |
| Other physical details |
charts , facsimiles ; |
| Dimensions |
25cm |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutical Chemistry |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Cancer has proven to be one of the most intractable diseases to which humans are subjected. Cancer chemotherapy play an important role in the treatment of cancer. It has entered a new era of molecular targeted therapeutics, which is highly selective and not associated with the serious toxicities of conventional cytotoxic drugs. Unfortunately, targeted chemotherapy still has some limitations. The chief among them is the potential of cells to develp resistance. As a result, in most cases, it is advantageous to use them in combination, either with other targeted therapy or with traditional therapy. One of the most critical therapeutic target in the treatment of cancer is mutated BRAF kinase enzyme (V600EBRAF), which is involved in approximately 30% of human cancers.The present study was constructed to design and synthesize 42 pyridopyrazinone derivatives in order to investigate their activities against different cancer cell lines in addition, to study the possible interaction with the active site of mutated BRAF kinase enzyme. The 42 pyridopyrazinone derivatives were synthesized according to reported methods and their structures were elucidated using spectral analysis such as IR, 1HNMR and Mass spectroscopy in addition to elemental analysis. The in vitro antitumor screening was evaluated for the synthesized compounds against different cell lines such as melanoma, ovarian, thyroid and colon cancer using MTT assay method for 25 compounds and SRB assay method for 17 compound using sorafenib and doxorubicin as standards, respectivily. The results revealed that some of these compounds have a promising activity against thyroid and colon cancer |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Additional physical form available note |
Issued also as CD |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Design, synthesis and molecular modeling |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Expected antineoplastic activity |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Novel pyridopyrazinone derivatives |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Doaa Ezzat Abdelrahman , |
| Relator term |
|
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Kamelia Mahmoud Amin , |
| Relator term |
|
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ossama Metwally Elbadry , |
| Relator term |
|
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) |
|---|
| Cataloger |
Enas |
| Reviser |
Cataloger |
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) |
|---|
| Cataloger |
Nazla |
| Reviser |
Revisor |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
